Mast Cells: A New Target for Diabetic Nephropathy
Diabetes remains a mounting health burden as more patients with chronic and uncontrolled diabetes develop progressively worse complications requiring extensive medical and surgical interventions. In many instances, chronically uncontrolled diabetes can injure the kidneys leading to diabetic nephropathy (DN). Among diabetics, DN patients have a worse prognosis and survival with many chronic kidney disease and end-stage renal disease (ESRD), which increases the demand for dialysis and surgical intervention. Despite several available pharmacological treatments, most fail to improve survival among DN patients. As a result, new pharmaceutical regiments for managing DN is critically needed. In recent years, pharmaceutical therapies targeting mast cells in DN have shown great potential to reduce renal inflammation and induce remodeling of damaged kidney structures. Further double-blind clinical trials are needed to evaluate the efficacy and safety of mast cell stabilizers among DN patients
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution - Non-Commercial 4.0 International License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in the Medical Student Press Journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).